PT Journal
AU Chrapek, O
   Jirkova, B
   Kandrnal, V
   Rehak, J
   Sin, M
TI Treatment of central serous chorioretinopathy with beta-blocker metipranolol
SO Biomedical papers
PY 2015
BP 120
EP 123
VL 159
IS 1
DI 10.5507/bp.2013.015
DE betablocker; central serous chorioretinopathy; metipranolol
AB Aim: The purpose of this study was to evaluate the effect of the systemically administered betablocker metipranolol on the course of central serous chorioretinopathy (CSC).Methods: A prospective double-blind study involving 48 patients with a first attack of CSC not exceeding two weeks and who agreed to the follow-up ophthalmology examinations every week. The group was divided into a metipranolol group (n=23), receiving 10 mg of drug twice per day and a placebo group (n=25). The outcome measure was time in weeks from drug intervention (metipranolol vs. placebo) to reattachment of macula neuroepithelium.Results: There was no statistically significant difference in duration of CSC in patients who used metipranolol and those who used placebo (P=0.341).Conclusions: In a prospective double-blind study, we found no effect of the betablocker metipranolol on the duration of central serous chorioretinopathy.
ER